Antibody-drug conjugates:design and clinical progress / 药学学报
Acta Pharmaceutica Sinica
;
(12): 1209-2016.
Article
in Chinese
| WPRIM
| ID: wpr-779298
ABSTRACT
Antibody-drug conjugates, constructed with monoclonal antibodies, linker and cytotoxins, have distinctive advantages over chemotherapy drugs and antibody drugs in cancer therapy. In this review, the strategy of developing ADCs, and the important progress in past decade are well summarized. The representative ADCs in the pipeline are introduced and characterized with their new features. While, perspective for future directions of ADCs is proposed.
Full text:
Available
Index:
WPRIM (Western Pacific)
Language:
Chinese
Journal:
Acta Pharmaceutica Sinica
Year:
2016
Type:
Article
Similar
MEDLINE
...
LILACS
LIS